[go: up one dir, main page]

CA3218345A1 - Agonistes macrocycliques du recepteur du peptide 1 de type glucagon - Google Patents

Agonistes macrocycliques du recepteur du peptide 1 de type glucagon Download PDF

Info

Publication number
CA3218345A1
CA3218345A1 CA3218345A CA3218345A CA3218345A1 CA 3218345 A1 CA3218345 A1 CA 3218345A1 CA 3218345 A CA3218345 A CA 3218345A CA 3218345 A CA3218345 A CA 3218345A CA 3218345 A1 CA3218345 A1 CA 3218345A1
Authority
CA
Canada
Prior art keywords
preparation
mmol
methyl
title compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218345A
Other languages
English (en)
Inventor
Francisco Javier Agejas Chicharro
Renato Alejandro BAUER
Michael Gregory Bell
Qi Chen
Graham Robert Cumming
Todd Fields
Douglas Linn Gernert
Joseph Daniel HO
Talbi Abelkader KAOUDI
Thierry Jean MASQUELIN
Jose Miguel Minguez Ortega
Julian PRIEGO SOLER
Antonio Rodriguez Hergueta
Eric Michael Woerly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3218345A1 publication Critical patent/CA3218345A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dans un mode de réalisation, la présente invention concerne un composé de formule : ou un sel pharmaceutiquement acceptable de celui-ci, et des méthodes d'utilisation de ce composé pour le traitement du diabète sucré de type II.
CA3218345A 2021-05-20 2022-05-19 Agonistes macrocycliques du recepteur du peptide 1 de type glucagon Pending CA3218345A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163191034P 2021-05-20 2021-05-20
US63/191,034 2021-05-20
US202163254564P 2021-10-12 2021-10-12
US63/254,564 2021-10-12
EP21383172.0 2021-12-21
EP21383172 2021-12-21
PCT/US2022/029958 WO2022246019A1 (fr) 2021-05-20 2022-05-19 Agonistes macrocycliques du récepteur du peptide 1 de type glucagon

Publications (1)

Publication Number Publication Date
CA3218345A1 true CA3218345A1 (fr) 2022-11-24

Family

ID=82016585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218345A Pending CA3218345A1 (fr) 2021-05-20 2022-05-19 Agonistes macrocycliques du recepteur du peptide 1 de type glucagon

Country Status (10)

Country Link
EP (1) EP4341255A1 (fr)
JP (1) JP7703691B2 (fr)
KR (1) KR20230173166A (fr)
AU (1) AU2022275931B2 (fr)
BR (1) BR112023022851A2 (fr)
CA (1) CA3218345A1 (fr)
IL (1) IL308397A (fr)
MX (1) MX2023013717A (fr)
TW (1) TWI843104B (fr)
WO (1) WO2022246019A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022349020A1 (en) 2021-09-27 2024-05-09 Terns Pharmaceuticals, Inc. Benzimidazole carboxylic acids as glp-1r agonists
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
JP2025508812A (ja) 2022-02-23 2025-04-10 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒアゴニストとしての化合物
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
WO2024102625A1 (fr) * 2022-11-11 2024-05-16 Eli Lilly And Company Agonistes de récepteur du peptide 1 de type glucagon
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025158275A1 (fr) 2024-01-24 2025-07-31 Pfizer Inc. Polythérapie utilisant des composés antagonistes du récepteur du polypeptide insulinotrope glucose-dépendant et des composés agonistes du récepteur glp-1
WO2025189141A1 (fr) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Méthodes de traitement de l'obésité et d'augmentation de la perte de poids
CN119219759A (zh) * 2024-10-22 2024-12-31 浙江工业大学 一种双水相萃取耦合反相柱层析分离纯化发酵液中glp-1类似物的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325530B (zh) 2016-12-16 2022-01-11 辉瑞大药厂 Glp-1受体激动剂及其用途
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
PL3806855T3 (pl) 2018-06-15 2023-07-24 Pfizer Inc. Agoniści receptora GLP-1 oraz ich zastosowania
EP3883928A4 (fr) 2018-11-22 2022-06-29 Qilu Regor Therapeutics Inc. Agonistes de glp-1r et leurs utilisations
PH12021552557A1 (en) * 2019-04-12 2022-07-04 Qilu Regor Therapeutics Inc Glp-1r agonists and uses thereof
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (fr) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 Modulateur du récepteur glp-1 à petites molécules
PH12022550932A1 (en) * 2019-10-25 2023-06-14 Gilead Sciences Inc Glp-1r modulating compounds
PE20221422A1 (es) 2019-11-15 2022-09-20 Ildong Pharmaceutical Co Ltd Agonista del receptor glp-1 y uso de este
ES3010351T3 (en) 2019-12-02 2025-04-02 Hyundai Pharm Co Ltd Glp-1 receptor agonist
AU2021212669B2 (en) 2020-01-29 2023-10-26 Gilead Sciences, Inc. GLP-1R modulating compounds
EP4103563A4 (fr) 2020-02-13 2024-03-06 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
IL296336A (en) 2020-03-18 2022-11-01 Lg Chemical Ltd Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN115667250A (zh) 2020-04-29 2023-01-31 加舒布鲁姆生物公司 杂环glp-1激动剂
KR102588241B1 (ko) 2020-06-04 2023-10-11 항저우 사이윈드 바이오사이언시즈 컴퍼니 리미티드 5원 헤테로방향족 이미다졸 화합물 및 이의 용도
CN115697338B (zh) 2020-06-10 2024-08-09 东宝紫星(杭州)生物医药有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN113801136B (zh) 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
TW202214610A (zh) 2020-06-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 ６－側氧－３，６－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
WO2021259309A1 (fr) 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Agoniste du récepteur glp-1, composition pharmaceutique et utilisation associées
KR20230053620A (ko) 2020-08-06 2023-04-21 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
AR123156A1 (es) 2020-08-06 2022-11-02 Qilu Regor Therapeutics Inc Agonistas de glp-1r y sus usos
MX2023002108A (es) 2020-08-21 2023-07-11 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r.
JP2023538949A (ja) 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
MX2023001980A (es) 2020-09-01 2023-02-27 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo.
CN115515956B (zh) 2020-09-29 2024-06-25 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
US20250263402A1 (en) 2020-10-12 2025-08-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Benzimidazolone glp-1 receptor agonist and use thereof
CN116547278A (zh) 2020-10-13 2023-08-04 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2022078407A1 (fr) 2020-10-13 2022-04-21 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用

Also Published As

Publication number Publication date
JP2024521073A (ja) 2024-05-28
TWI843104B (zh) 2024-05-21
MX2023013717A (es) 2024-01-16
IL308397A (en) 2024-01-01
EP4341255A1 (fr) 2024-03-27
BR112023022851A2 (pt) 2024-01-23
AU2022275931B2 (en) 2024-08-15
KR20230173166A (ko) 2023-12-26
WO2022246019A1 (fr) 2022-11-24
JP7703691B2 (ja) 2025-07-07
AU2022275931A1 (en) 2023-11-02
TW202310838A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
CA3218345A1 (fr) Agonistes macrocycliques du recepteur du peptide 1 de type glucagon
CA3144055C (fr) Agonistes du recepteur du peptide de type glucagon 1
AU2024227155A1 (en) Carboxy-benzimidazole GLP-1R modulating compounds.
EP2038272B1 (fr) Inhibiteurs de pyridinonyle pdk1
CN102665718B (zh) 可用作pdk1抑制剂的杂环化合物
CN102264707B (zh) 双环型杂环化合物
US10017502B2 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
WO2011075560A1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
JP2017001991A (ja) 新規ベンズオキサゾロン化合物
TW200914449A (en) Organic compounds
AU2018257203B2 (en) Novel tetrahydronaphthyl urea derivatives
TWI843949B (zh) 黑皮質素4(melanocortin 4)受體拮抗劑及其用途
JP2025537254A (ja) グルカゴン様ペプチド１受容体アゴニスト
KR20250085816A (ko) 글루카곤-유사 펩티드 1 수용체 효능제
JP6797923B2 (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
CA2828518C (fr) Derives de pyridynyl- et pyrasinyl-methyloxy-aryl utiles comme inhibiteurs de tyrosine kinase spleniqueyk)
EP3807273B1 (fr) Dérivés d'azaindole comme inhibiteurs de la kinase rho
RU2662157C2 (ru) 2-пиридоновое соединение
CN107250126B (zh) 长效二肽基肽酶-iv抑制剂、其用途及其制备方法
US20240343740A1 (en) Macrocyclic glucagon-like peptide 1 receptor agonists
CN117355517A (zh) 大环胰高血糖素样肽1受体激动剂
WO2025264700A1 (fr) Composés agonistes du récepteur gip
EA048136B1 (ru) Спиросоединения в качестве антагонистов рецептора меланокортина 4 и их применения
HK1207856B (en) 2-pyridone compound
KR20110109917A (ko) 신규한 퀴녹살린 유도체

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231107

EEER Examination request

Effective date: 20231107

EEER Examination request

Effective date: 20231107